ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1348	National Cancer Institute	Html	en	Childhood Brain and Spinal Cord Tumors Treatment Overview (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of various childhood brain tumors.	extent 0.337038 subsequent treatment 0.517666 Secondary tumors 0.579906 clinical parameters 0.491035 tumor recurrence. 0.623825 survival rates 0.51115 Long-term management 0.517392 chemotherapy 0.381898 cancer therapy 0.545899 complete evaluation 0.500262 malignant tumors 0.805007 malignant lesions. 0.574087 surgical re-resection 0.493219 need 0.367173 adolescents 0.338935 treatment-related brain necrosis 0.687273 diagnosis 0.335644 long-term survivors. 0.521208 secondary tumor 0.621568 delay 0.350588 radiation therapy 0.839862 reappearance 0.354633 Long-term sequelae 0.545468 late effects 0.655763	initial presence 0.550902 childhood cancer mortality 0.80921 CNS 0.340422 surgical intervention 0.48867 Systemic relapse 0.562929 Refer 0.342732 multidisciplinary approach 0.498495 specific information 0.517079 lower-grade lesions 0.50599 preliminary results 0.50527 molecular makeup. 0.495814 initial tumor type 0.822989 initial treatment 0.69405 primary tumor site 0.789307 close monitoring 0.52126 tumor transformation 0.62382 younger children 0.509243 adolescent cancer survivors 0.999281 childhood brain tumors 0.792254 Dramatic improvements 0.534814 PDQ summary 0.529827 Biopsy 0.34098 neurologic development 0.517779 time 0.38324	CLICK HERE
1375	National Cancer Institute	Html	en	Cancer Screening Overview (PDQ®)–Health Professional Version	Information about measuring the effectiveness of cancer screening tests and about weighing the strength of the evidence obtained from cancer screening research studies.	PDQ Screening 0.435302 cancer antigen 0.351044 cancer screening interventions 0.511292 advanced-stage pancreatic cancer 0.361147 cancer screening 0.938139 lung cancer screening 0.519031 new screening test 0.500274 cancer prevention 0.350991 Interval cancer events 0.364348 new screening modality 0.453389 IIIB–IV lung cancer 0.361117 prostate screening 0.417963 lung cancer rates 0.355466 prostate cancer treatment 0.3549 mammography screening 0.457867 screening program 0.415447 screening summaries 0.435473 disease-specific mortality 0.409334 cancer cases 0.346604 whole-body screening technologies 0.500642 lower cancer risk 0.359738 interval cancer rates 0.358328 colorectal cancer 0.351483 routine cancer screening 0.555956	recent screening 0.436851 false-negative screening test 0.511207 older screening modalities 0.448481 breast cancer 0.418358 cancer diagnosis 0.374736 prostate cancer screening 0.551218 actual cancer risk 0.422669 cancer screening tests 0.659235 randomized controlled trial 0.36573 prostate cancer mortality. 0.348853 false-positive screening results 0.509129 screening center 0.444606 fecal occult blood 0.356414 higher cancer risk 0.360321 cancer mortality. 0.353113 decision making 0.410621 all-cause mortality 0.362129 breast cancer overdetection 0.35093 routine screening mammographies 0.474709 randomized clinical trials 0.34952 Cancer Screening Trial 0.566983 invasive diagnostic procedures 0.355819 routine PSA screening 0.472621	CLICK HERE
1468	National Cancer Institute	Html	null	Testicular Cancer Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of testicular cancer.			CLICK HERE
1706	National Cancer Institute	Html	en	Tumor Markers	A fact sheet that defines tumor markers and describes how they can be used to aid diagnosis and treatment.	average risk 0.450619 Urokinase plasminogen activator 0.459684 EGFR gene mutation 0.458827 low recurrence rates 0.462003 potential markers 0.487538 tumor marker 0.811954 Laboratory Improvement Amendments 0.454191 Cancer researchers 0.453927 tumor tissue 0.581622 prostate cancer deaths 0.482408 cancer cells 0.464646 randomized controlled trials 0.451211 cancer therapy 0.462023 Programmed death ligand 0.453669 certain tumor markers 0.637279 Tumor marker levels 0.59758 tumor cells 0.533609 hormone therapy 0.468386 plasminogen activator inhibitor 0.458435 Ovarian Cancer Screening 0.481982 oncotype dx® 0.458204 NCI-sponsored Trial Assigning 0.453214 cancer care 0.460826 European Randomized Study 0.452179	benign prostate conditions 0.461678 BRAF V600 mutations 0.455095 tumor markers 0.944185 ovarian cancer 0.509174 gene mutation 0.459648 Diagnosis research page 0.451878 cancer types 0.497466 BCR-ABL fusion gene 0.458705 follow-up diagnostic tests 0.453464 Beta-human chorionic gonadotropin 0.457581 prostate cancer 0.504684 KRAS gene mutation 0.459458 elevated PSA level 0.472298 ALK gene rearrangements 0.462612 cancer staging 0.458494 accurate tumor markers 0.611174 cancer recurrence 0.463465 different tumor markers 0.654628 HER2-negative breast cancer 0.476048 noncancerous) conditions. 0.470899 cancer 0.625548 Nuclear matrix protein 0.450815 gene expression 0.46063	CLICK HERE
1721	National Cancer Institute	Html	en	Cruciferous Vegetables and Cancer Prevention	A fact sheet that summarizes the results of studies about cruciferous vegetables and cancer. Includes a list of cruciferous vegetables and dietary recommendations.	Netherlands—the Netherlands Cohort 0.505069 vegetable consumption 0.464589 cruciferous vegetables 0.977553 additional cohort study 0.516082 lung cancer 0.572949 anticancer effects 0.474858 colorectal cancer risk 0.625293 U.S. analysis—using data 0.461382 Breast Cancer Detection 0.503706 case-control studies 0.513186 prostate cancer risk 0.623248 lower risk 0.488713 glutathione S-transferase M1 0.504449 American Journal 0.4921 cruciferous vegetable intakes 0.595836 dark-green vegetables 0.522884 cancer chemopreventive actions 0.501377 cruciferous vegetable intake 0.689816 Cancer Epidemiology 0.57031 cohort studies 0.539353 glutathione S-transferase polymorphisms 0.4667 European Prospective Investigation 0.461912 cohort study 0.686602 cancer prevention 0.479265 United States 0.545427	Different vegetables 0.524746 multiethnic case-control study 0.487149 National Cancer Institute 0.594926 Project follow-up cohort 0.488384 Multiethnic Cohort Study 0.506189 good fiber source 0.467963 cancer researchers 0.489622 prospective cohort study 0.510047 breast cancer risk 0.615894 fruit consumption 0.483024 Clinical Nutrition 0.460261 breast cancer 0.641649 colon cancer risk 0.523965 biologically active compounds 0.464394 Goldbohm RA 0.48606 lung cancer risk 0.545247 C. Brassica vegetables 0.534883 prospective study 0.585742 glutathione S-transferase 0.517935 lung cancer mortality 0.501562 et al 0.817121 cancer risk 0.800364 Netherlands Cohort Study 0.590813 lower lung cancer 0.502455	CLICK HERE
1771	National Cancer Institute	Html	es	Sofocos y sudores nocturnos (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca de las causas y el tratamiento de los sofocos y sudores nocturnos en los pacientes de cáncer.	cancer treatment 0.37896 Treatment Group Trial 0.316121 ncctg trial 0.313822 Treatment Group hot 0.319139 menopausal hot 0.328045 Loprinzi CL 0.615617 trial with 0.311 menopausal symptoms 0.33934 Sin embargo 0.333136 Barton DL 0.356229 with early stage 0.313223 black cohosh 0.329892 Sloan JA 0.313934 ameliorating tamoxifen-induced hot 0.310913 randomized trial 0.317475 with hot 0.314342 phase iii 0.323066 active nonhormonal hot 0.311258 symptoms after breast 0.31045 Natl Cancer Inst 0.330125 during menopausal hot 0.313013 North Central Cancer 0.333247 tamoxifen-induced hot 0.32746 Women's Health Initiative 0.336331 Cancer Ther 0.316362	breast carcinoma 0.310376 Support Oncol 0.317335 randomized controlled 0.353057 Initiative Randomized Trial 0.310959 Cognitive behavioural treatment 0.310884 hot flash studies 0.31899 Hot Flash Related 0.322478 experiencing tamoxifen-induced hot 0.310785 problematic menopausal hot 0.31265 hierba sonajero 0.329084 estrogen replacement therapy 0.321006 Support Care Cancer 0.31053 Cancer Res Treat 0.338604 Cancer Treatment Group 0.35326 after breast 0.314947 Clin Oncol 0.532082 breast cancer 0.920092 health initiative randomized 0.310524 hot flash 0.362781 Pilot evaluation 0.324608 early stage breast 0.318416 Central Cancer Treatment 0.352938 learned from hot 0.311156 Stearns V 0.318536	CLICK HERE
1777	National Cancer Institute	Html	es	El dolor y el cáncer (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del dolor como una complicación a causa del cáncer o su tratamiento. Se tratan abordajes para el control y el tratamiento del dolor relacionado con el cáncer.	Moderate Cancer Pain 0.337641 among patients with 0.313833 Curr Pain Headache 0.353041 Palliat Nurs 0.30942 Chronic Pain Syndromes 0.356907 Breakthrough Pain Study 0.329475 Pain Questionnaire 0.327384 Jensen MP 0.310829 Cancer Therapy 0.30947 with breast cancer 0.313155 Edmonton Symptom Assessment 0.309493 Pain Terms 0.351866 pain management 0.434176 Natl Cancer Inst 0.310759 Hui D 0.310443 pain syndromes 0.398674 Faces Pain Scale 0.329845 Pain Res 0.344114 patients with 0.479951 Pain Symptom Manage 0.524062 Pain Experience among 0.326556 Pain Management Nursing 0.328639 chronic pain 0.526592 dolor).¿El dolor 0.346176 Oncol Nurs Forum 0.309327	peor dolor 0.357775 pain assessment 0.342098 Care Cancer 0.331083 breakthrough pain 0.366572 palliative care 0.309739 Hosp Palliat Care 0.329839 Faces Pain 0.365306 Pain related 0.328906 pain assessment toolkit 0.327388 pain control 0.351552 patients with depression 0.30909 Brief Pain Inventory 0.377512 Pain Headache Rep 0.352431 cancer pain 0.974628 cancer pain prognostic 0.363979 pain experience 0.342944 Clin Oncol 0.363176 Palliat Med 0.324432 pain's interference with 0.332203 breast cancer 0.321556 Bruera E 0.316817 edmonton staging system 0.310908 systematic review 0.31986 Faces Pain Scale-Revised 0.327413	CLICK HERE
3578	National Cancer Institute	Html	en	Research Areas	Making sustained progress against cancer requires advances across the research continuum. Learn about the breadth of NCI's work and the programs the institute supports to advance cancer research.	National Cancer Institute 0.966549		CLICK HERE
4329	National Cancer Institute	Html	en	Cancer Screening	A summary of the benefits and possible harms of cancer screening tests.	time symptoms 0.320649 abnormal tissue 0.346264 False-negative test results 0.440391 screening tests 0.953871 false reassurance 0.328265 potential harms 0.743558 different cancer screening 0.573019 medical care 0.312433	people 0.200595 Early detection 0.319119 additional tests 0.299571 health problems 0.324983 doctors 0.208104 False-positive test results 0.450006 cancer 0.861445	CLICK HERE
14600	National Cancer Institute	Html	es	Tratamiento de los tumores vasculares infantiles (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento de los tumores vasculares infantiles.	Natl Acad Sci 0.324634 anomalías vasculares retinianas 0.33309 hemangiomas is directly 0.365854 lesiones benignas 0.319493 Infants With Infantile 0.316042 lesiones precursoras 0.322133 frecuencia cardíaca 0.363288 cells from hemangiomas 0.365897 Denise Adams 0.34719 Ampliar Figura 0.334799 hemangiomas perioculares subcutáneos 0.383239 propranolol quizás 0.334782 Prospective study 0.315057 capillary hemangioma 0.369091 International Society 0.348608 vasculares hepáticos benignos 0.326723 tumores vasculares benignos 0.402681 Léauté-Labrèze C 0.314686 evaluación cardíaca 0.323474 angiofibromas nasofaríngeos 0.342724 síndrome phace 0.577507 angiofibroma nasofaríngeo 0.314735 anomalías renales 0.316886 Children With Infantile 0.315749 oral propranolol 0.362065	Clin Invest 0.327186 hemangiomas congénitos 0.761656 endothelial cells 0.315693 hemangiomas cutáneos 0.372477 Arch Dermatol 0.329954 Cuadro clínico 0.393896 Proc Natl Acad 0.325302 infantile hemangiomas 0.938164 With Infantile Hemangioma 0.438965 Nadolol Versus Propranolol 0.33549 vías respiratorias 0.521847 granuloma piógeno 0.329351 Vascular Anomalies Classification 0.319289 insuficiencia cardíaca transitoria 0.335633 antecedentes familiares 0.32937 hemangioma cutáneo congénito 0.383839 Complicated Vascular Anomalies 0.316136 Benigno Hemangioma 0.393265 Drolet BA 0.324986 lesiones cutáneas 0.338858 clasificación issva 0.316546 Blei F 0.314967 hemangioma epitelioide 0.552561 Hoeger P 0.315823	CLICK HERE